Dalmelitinib
Cat. No.: IBDI-437273
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC).
Product Details
Target |
c-Met/HGFR |
Molecular Weight |
461.47 |
SMILES |
O=C1N(C)C2=CN=C3C=CC(SC4=NN=C5C(F)=CC(C6=CN(C)N=C6)=CN45)=CC3=C2OC1 |
Storage & Handling
Shipping |
Room temperature in continental US. May vary elsewhere. |
Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.